The content on this page is designed for Australia. Check courses designed for Canada (EN)

This course has expired. View available courses.

Infectious Disease

Eliminating Hepatitis C: What GPs need to know

Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver, but is also responsible for extra-hepatic manifestations such as porphyria, increased risk of lymphoma and diabetes. The introduction of direct-acting antiviral (DAA) therapies, which can cure HCV in the majority of patients, represents a major advance – and all Australians living with HCV should now be considered for DAA therapy. However, 121,560 people were estimated to still living be living with chronic HCV at the end of 2019 highlighting the need for improved diagnosis and treatment uptake.

This 1-hour RACGP accredited activity aims to empower GPs to implement a simple, evidence-based approach to identify and manage patients with HCV. It features two cases studies.


This program is supported by an independent and unrestricted educational grant by Gilead.

DURATION

1 hr

PROFESSION

Physician

# OF CREDITS

2

ACCREDITATION

RACGP CPD Program

EXPIRY DATE

2022-12-15

Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver, but is also responsible for extra-hepatic manifestations such as porphyria, increased risk of lymphoma and diabetes. The introduction of direct-acting antiviral (DAA) therapies, which can cure HCV in the majority of patients, represents a major advance – and all Australians living with HCV should now be considered for DAA therapy. However, 121,560 people were estimated to still living be living with chronic HCV at the end of 2019 highlighting the need for improved diagnosis and treatment uptake.

This 1-hour RACGP accredited activity aims to empower GPs to implement a simple, evidence-based approach to identify and manage patients with HCV. It features two cases studies.


This program is supported by an independent and unrestricted educational grant by Gilead.

Faculty

Associate Professor Stephen Pianko, MBBS, PhD,
Gastroenterologist and Hepatologist, Monash University,
Head of Clinical Trials, Monash Health, Melbourne, Victoria

Dr Annie Balcomb, MBBS, FRACGP, S100 HSV Prescriber,
Part time lecturer, Sydney University,
Orange Rural Medical Campus, Orange, NSW

Professor Alex Thompson, MBBS (hons), PhD, FRACP, FAASLD
Director of Gastroenterology, St. Vincent’s Hospital Melbourne

Learning objectives

On completion of this program, GPs will be better able to:

  • Describe the current burden of HCV disease and how Australia is tracking for WHO 2030 HCV elimination goals
  • List the benefits of sustained virological response (SVR) in HCV patients highlighting the reduction in HCV disease complications
  • Implement a simple, evidence-based approach to identify patients with HCV
  • Recommend a suitable treatment approach for individual patients, and counsel patients on their HCV treatment
  • Identify patients living with HCV who require referral to specialist services

Accreditation

This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.

Activity no. 288670

Cost of course:  
Free
# of credits: 2
Duration: 1 hr

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.

Eliminating Hepatitis C: What GPs need to know

1 hr

Duration

Physician

Profession

2

# of credits

Learning Objectives

On completion of this program, GPs will be better able to:

  • Describe the current burden of HCV disease and how Australia is tracking for WHO 2030 HCV elimination goals
  • List the benefits of sustained virological response (SVR) in HCV patients highlighting the reduction in HCV disease complications
  • Implement a simple, evidence-based approach to identify patients with HCV
  • Recommend a suitable treatment approach for individual patients, and counsel patients on their HCV treatment
  • Identify patients living with HCV who require referral to specialist services

RACGP CPD Program

ACCREDITATION

Infectious Disease

Learning Category

Hepatitis C

Topic

0

Price

2022-12-15

Expiry Date

AUS

Region/Language

Course Description

Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver, but is also responsible for extra-hepatic manifestations such as porphyria, increased risk of lymphoma and diabetes. The introduction of direct-acting antiviral (DAA) therapies, which can cure HCV in the majority of patients, represents a major advance – and all Australians living with HCV should now be considered for DAA therapy. However, 121,560 people were estimated to still living be living with chronic HCV at the end of 2019 highlighting the need for improved diagnosis and treatment uptake.

This 1-hour RACGP accredited activity aims to empower GPs to implement a simple, evidence-based approach to identify and manage patients with HCV. It features two cases studies.


This program is supported by an independent and unrestricted educational grant by Gilead.

Faculty

Associate Professor Stephen Pianko, MBBS, PhD,
Gastroenterologist and Hepatologist, Monash University,
Head of Clinical Trials, Monash Health, Melbourne, Victoria

Dr Annie Balcomb, MBBS, FRACGP, S100 HSV Prescriber,
Part time lecturer, Sydney University,
Orange Rural Medical Campus, Orange, NSW

Professor Alex Thompson, MBBS (hons), PhD, FRACP, FAASLD
Director of Gastroenterology, St. Vincent’s Hospital Melbourne

Accreditation

This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.

Activity no. 288670